María C. Zamorano Andrés

Hospital de Hellín

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

ÁL

Álex Larruzea

Institut de Seguretat Pública de Catalunya

María Arnaldos Carrillo

Hospital Universitario Virgen de la Arrixaca

Elisa Nuez‐Zaragoza

Corporació Sanitària Parc Taulí

Patricia Esteban Torrella

Hospital Reina Sofía de Murcia

Juan Adell Ruiz de León

Hospital Clínico Universitario Virgen de la Victoria

Iria Cebreiros López

Hospital Universitario Virgen de la Arrixaca

Amaia Fernandez-Uriarte

Mount Sinai Hospital

Mercedes González Morales

Santa Lucía University General Hospital

Alicia Ruiz Ripa

Hospital de Mataró

José M. Egea-Caparrós

Hospital General Universitario Los Arcos del Mar Menor

Cooperative Institutions

Sociedad Española de Medicina Interna

Santa Lucía University General Hospital

Spanish Society of Family and Community Medicine

Universitat Autònoma de Barcelona

Hospital Universitario Virgen de la Arrixaca

Complejo Hospitalario Universitario de Toledo

Instituto Murciano de Investigación Biosanitaria

Hospital Rafael Méndez

Corporació Sanitària Parc Taulí

Institute of Research and Innovation Parc Tauli

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Characteristics and laboratory findings on admission to the emergency department among 2873 hospitalized patients with COVID-19: the impact of adjusted laboratory tests in multicenter studies. A multicenter study in Spain (BIOCOVID-Spain study)

Scandinavian Journal of Clinical and Laboratory Investigation (2021)

Luis García de Guadiana‐Romualdo Daniel Morell‐García Cristian Morales‐Indiano Josep Miquel Bauçà Maria José Alcaide Martín

Identification of predictors for severe disease progression is key for risk stratification in COVID-19 patients. We aimed to describe the main characteristics and identify the early predictors for severe outcomes among hospitalized patients with COVID-19 in Spain. This was an observational, retrospective cohort study (BIOCOVID-Spain study) including COVID-19 patients admitted to 32 Spanish hospitals. Demographics, comorbidities and laboratory tests were collected. Outcome was in-hospital mortality. For analysis, laboratory tests values were previously adjusted to assure the comparability of results among participants. Cox regression was performed to identify predictors. Study population included 2873 hospitalized COVID-19 patients. Nine variables were independent predictors for in-hospital mortality, including creatinine (Hazard ratio [HR]:1.327; 95% Confidence Interval [CI]: 1.040-1.695, p = .023), troponin (HR: 2.150; 95% CI: 1.155-4.001; p = .016), platelet count (HR: 0.994; 95% CI: 0.989-0.998; p = .004) and C-reactive protein (HR: 1.037; 95% CI: 1.006-1.068; p = .019). This is the first multicenter study in which an effort was carried out to adjust the results of laboratory tests measured with different methodologies to guarantee their comparability. We reported a comprehensive information about characteristics in a large cohort of hospitalized COVID-19 patients, focusing on the analytical features. Our findings may help to identify patients early at a higher risk for an adverse outcome.

10.1080/00365513.2021.1881997

Cite

Citations (23)

Cardiac troponin and COVID‐19 severity: Results from BIOCOVID study

European Journal of Clinical Investigation (2021)

Luis García de Guadiana‐Romualdo Daniel Morell‐García Olaia Rodríguez‐Fraga Cristian Morales‐Indiano Ana María Lourdes Padilla Jiménez

Abstract Background Myocardial injury is a common finding in COVID‐19 strongly associated with severity. We analysed the prevalence and prognostic utility of myocardial injury, characterized by elevated cardiac troponin, in a large population of COVID‐19 patients, and further evaluated separately the role of troponin T and I. Methods This is a multicentre, retrospective observational study enrolling patients with laboratory‐confirmed COVID‐19 who were hospitalized in 32 Spanish hospitals. Elevated troponin levels were defined as values above the sex‐specific 99th percentile upper reference limit, as recommended by international guidelines. Thirty‐day mortality was defined as endpoint. Results A total of 1280 COVID‐19 patients were included in this study, of whom 187 (14.6%) died during the hospitalization. Using a nonspecific sex cut‐off, elevated troponin levels were found in 344 patients (26.9%), increasing to 384 (30.0%) when a sex‐specific cut‐off was used. This prevalence was significantly higher (42.9% vs 21.9%; P < .001) in patients in whom troponin T was measured in comparison with troponin I. Sex‐specific elevated troponin levels were significantly associated with 30‐day mortality, with adjusted odds ratios (ORs) of 3.00 for total population, 3.20 for cardiac troponin T and 3.69 for cardiac troponin I. Conclusion In this multicentre study, myocardial injury was a common finding in COVID‐19 patients. Its prevalence increased when a sex‐specific cut‐off and cardiac troponin T were used. Elevated troponin was an independent predictor of 30‐day mortality, irrespective of cardiac troponin assay and cut‐offs to detect myocardial injury. Hence, the early measurement of cardiac troponin may be useful for risk stratification in COVID‐19.

Troponin T

10.1111/eci.13532

Cite

Citations (58)

Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study)

Journal of Thrombosis and Thrombolysis (2021)

Luis García de Guadiana‐Romualdo Daniel Morell‐García Emmanuel J. Favaloro Juan A. Vílchez Josep Miquel Bauçà

D-dimer

Clinical endpoint

10.1007/s11239-021-02527-y

Cite

Citations (24)